English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Recent Confirmed OrdersLast 7 days
Australia2 gTirzepatide 100 mg · CagriSema 20 mg · BPC-157 10 mg · TB-500 5 mg · Melanotan II 10 mg · PT-141 10 mg · Bacteriostatic Water 3 ml
View all

Repair and regenerative research

TB-500

N-acetylated LKKTETQ thymosin-β4 fragment research reference

Lot-specific chromatographic purity plus quantitative peptide content; confirm N-acetylation, terminal form, counterion, water and related peptides separately · target, verify batch COACAS 885340-08-9RUO
Research statusFragment-specific preclinical and analytical evidence is limited; much cited clinical evidence concerns full-length thymosin-β4, not this fragment
Supplied formLinear N-acetylated heptapeptide corresponding to thymosin-β4 residues 17–23
Lead time7–14 days
TB-500 — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA
TB-500 — Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • Defensible research value includes actin-related mechanism hypotheses, fragment-versus-parent comparisons, cell-migration and wound-model experiments, analytical identification and anti-doping method development
  • Claims of systemic tissue repair, athletic recovery, angiogenesis or clinical wound benefit are not established for this isolated fragment and must remain hypotheses or parent-molecule background.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
885340-08-9
Formula
C38H68N10O14
Molecular weight
889.0 g/mol
Appearance
Lot-specific lyophilized research peptide; confirm colour and physical form on the released-lot COA
Purity
Lot-specific chromatographic purity plus quantitative peptide content; confirm N-acetylation, terminal form, counterion, water and related peptides separately · target, verify batch COA
Storage
Follow the released-lot label, COA and fragment-specific stability data. Do not assume 2–8°C storage, a 28-day reconstituted period or finished-formulation instructions without supporting data for the supplied terminal form, counterion, matrix and container.
MOQ
On request
Lead time
7–14 days
PubChem CID 62707662

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about TB-500

This catalogue record defines TB-500 as the N-acetylated seven-residue sequence Ac-LKKTETQ corresponding to thymosin-β4 residues 17–23. PubChem CID 62707662 lists formula C₃₈H₆₈N₁₀O₁₄, molecular weight 889.0 g/mol and CAS 885340-08-9. The fragment is chemically distinct from full-length 43-residue thymosin-β4 and the RGN-259 clinical programme. Commercial naming is inconsistent, so sequence and mass—not the name alone—must control identity. Direct controlled human evidence for the isolated fragment was not identified; full-length clinical results must not be reassigned to it. The 2026 WADA Prohibited List names thymosin-β4 and its derivatives, including TB-500, under S2.3.

  • Appropriate laboratory contexts include fragment identity and N-acetylation, actin-related assays, fragment-versus-full-length comparisons, cell migration and repair models, proteolytic stability, formulation and analytical anti-doping research
  • No approved clinical indication applies to this fragment.

Mechanism context

The question the literature is testing

The LKKTETQ region is associated with actin-binding biology in the thymosin-β4 literature, but isolating and N-acetylating seven residues can change conformation, stability, distribution and potency. Parent-protein mechanisms cannot establish equivalent systemic action of the fragment. Experimental interpretation requires authenticated full-length and fragment controls, defined concentration, matrix and quantitative recovery.

Evidence map

Research routes and exposure context

Evidence tierMixed evidence context
Routes reported in sources
No administration route applies
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • Not for human or veterinary administration
  • Controlled human safety data for the isolated fragment were not identified, and full-length thymosin-β4 experience cannot establish fragment safety
  • Identity confusion, incorrect content, impurities, aggregation, contamination and unvalidated endotoxin or sterility are material risks
  • The 2026 WADA Prohibited List names thymosin-β4 and its derivatives, including TB-500, under S2.3.

Interactions reported in the literature

  • No human combination or compatibility guidance applies
  • Wolverine Blend, BPC-157, CJC-1295, IGF-1, ipamorelin, GHRP-6 and melanotan-II synergy claims were removed because vendor or community co-use does not establish pharmacological interaction, efficacy or safety
  • Laboratory mixtures require single-component controls and component-resolved analysis.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

TB-500 factory batch COAs

TB-500 2 mg Factory batch COA protected previewTB-5002 mg · WHJLP-TB2-260603-A
TB-500 5 mg Factory batch COA protected previewTB-5005 mg · WHJLP-TB5-260603-A
TB-500 10 mg Factory batch COA protected previewTB-50010 mg · WHJLP-TB10-260603-A
Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

  • Require Ac-LKKTETQ sequence and N-acetylation confirmation, intact mass, peptide mapping or tandem-MS where appropriate, chromatographic purity, quantitative peptide content, terminal and salt form, counterion, water, residual solvents, related peptides, container integrity and lot-specific stability
  • A clear reconstituted solution or a generic COA does not prove identity, content, sterility or stability.
Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
TB500-02MG2 mg10 vials
TB500-05MG5 mg10 vials
TB500-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot label, COA and fragment-specific stability data. Do not assume 2–8°C storage, a 28-day reconstituted period or finished-formulation instructions without supporting data for the supplied terminal form, counterion, matrix and container.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • Identity: PubChem CID 62707662, sequence Ac-LKKTETQ-OH, formula C₃₈H₆₈N₁₀O₁₄, molecular weight 889.0 g/mol and CAS 885340-08-9. Analytical context: Ho et al., Journal of Chromatography A 2012, PMID 23084823, detected the N-acetylated fragment and metabolites in equine samples; it is not human pharmacokinetic or efficacy evidence. Parent boundary: full-length thymosin-β4 comprises 43 residues, PMCID PMC319967, and RGN-259 literature concerns the full-length molecule. Anti-doping context: official 2026 WADA Prohibited List, S2.3.
  1. 01

    Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential

    Drug Testing and Analysis · 2012 · peer-reviewed original research (analytical/forensic chemistry)

    Open source
  2. 02

    The actin binding site on thymosin beta4 promotes angiogenesis

    The FASEB Journal · 2003 · peer-reviewed original research

    Open source
  3. 03

    Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

    Nature · 2004 · peer-reviewed original research (landmark/highly cited)

    Open source
  4. 04

    Progress on the function and application of thymosin β4

    Frontiers in Endocrinology · 2021 · peer-reviewed review article

    Open source
  5. 05

    0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

    International Journal of Molecular Sciences · 2022 · peer-reviewed original research (Phase III randomized controlled clinical trial, published as journal article)

    Open source
  6. 06

    Thymosin Beta 4 Protects Cardiomyocytes from Oxidative Stress by Targeting Anti-Oxidative Enzymes and Anti-Apoptotic Genes

    PLOS ONE · 2012 · peer-reviewed original research

    Open source
  7. 07

    Systemic Dosing of Thymosin Beta 4 before and after Ischemia Does Not Attenuate Global Myocardial Ischemia-Reperfusion Injury in Pigs

    Frontiers in Pharmacology · 2016 · peer-reviewed original research (large-animal preclinical study; negative/cautionary result)

    Open source
  8. 08

    The 2026 Prohibited List — Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics

    World Anti-Doping Agency · 2026 · regulatory/anti-doping prohibited substances list

    Open source

Product FAQ

Questions buyers ask about TB-500

Is this TB-500 record the same material as full-length thymosin-β4?+

No. This catalogue identity is the N-acetylated seven-residue sequence Ac-LKKTETQ, corresponding to residues 17–23. Full-length thymosin-β4 is a separate 43-residue peptide with different mass, CAS identity and evidence. The product name alone is ambiguous in commercial channels, so sequence, intact mass and released-lot form must control procurement.

Can RGN-259 dry-eye or corneal-healing trials support this fragment?+

Not as direct clinical evidence. RGN-259 studies used full-length thymosin-β4, not the isolated Ac-LKKTETQ fragment. Those studies may provide parent-molecule background, but fragment-specific activity, exposure, formulation, safety and efficacy require their own evidence and must not be inferred from the full-length programme.

What evidence should confirm a TB-500 fragment lot?+

Request the Ac-LKKTETQ sequence and N-acetylation assignment, intact mass, peptide mapping or tandem-MS where appropriate, chromatographic purity, quantitative peptide content, terminal and salt form, counterion, water, residual solvents, related peptides, container integrity and lot-specific stability. Endotoxin, bioburden and sterility are separate study-dependent attributes.

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Repair and regenerative research

BPC-157

Synthetic gastric pentadecapeptide research reference · preclinical evidence predominates

Purity
Target ≥ 99.0% · Batch COA
CAS
137525-51-0
Latest batch COA available on request
Repair and regenerative research

BPC-157 + TB-500 (Wolverine Stack)

BPC-157 + Ac-LKKTETQ two-peptide research pairing · no established biological synergy

Purity
Component-specific · Batch COA
CAS
137525-51-0
Latest batch COA available on request
Repair and regenerative research

GHK-Cu

Copper(II)-complexed GHK tripeptide · supplied form and copper stoichiometry are procurement-critical

Purity
Lot-specific · Batch COA
CAS
89030-95-5
Latest batch COA available on request
Repair and regenerative research

TB500 Fragment (Frag 17-23)

N-acetylated thymosin-β4 residues 17–23 research fragment · not full-length thymosin-β4

Purity
Lot-specific · Batch COA
CAS
885340-08-9
Latest batch COA available on request